{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:45:42Z","timestamp":1795005942616,"version":"4.9.1"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1NS090934"],"award-info":[{"award-number":["RF1NS090934"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1AG047644"],"award-info":[{"award-number":["RF1AG047644"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U19AG069701"],"award-info":[{"award-number":["U19AG069701"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer\u2019s Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41591-023-02505-2","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T04:14:13Z","timestamp":1693887253000},"page":"2187-2199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":382,"title":["Emerging diagnostics and therapeutics for Alzheimer disease"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-6124","authenticated-orcid":false,"given":"Wade K.","family":"Self","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0856","authenticated-orcid":false,"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"2505_CR1","unstructured":"World Health Organization. Ageing and health. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health (2022)."},{"key":"2505_CR2","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s Disease Facts and Figures. Alzheimer\u2019s Disease and Dementia https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures"},{"key":"2505_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. J. Am. Med. Assoc. 330, 512\u2013527 (2023).","journal-title":"J. Am. Med. Assoc."},{"key":"2505_CR5","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105\u2013e125 (2022).","journal-title":"Lancet Public Health"},{"key":"2505_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt, L. et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimer\u2019s Dement. 15, 888\u2013898 (2019).","journal-title":"Alzheimer\u2019s Dement."},{"key":"2505_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"2505_CR9","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D. & Rabinovici, G. D. The role of amyloid PET in imaging neurodegenerative disorders: a review. J. Nucl. Med. 63, 13S\u201319S (2022).","journal-title":"J. Nucl. Med."},{"key":"2505_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312\u2013339 (2019).","journal-title":"Cell"},{"key":"2505_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner, G. G. & Wong, C. W. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885\u2013890 (1984).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2505_CR12","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245\u20134249 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2505_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1126\/science.2111584","volume":"248","author":"E Levy","year":"1990","unstructured":"Levy, E. et al. Mutation of the Alzheimer\u2019s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124\u20131126 (1990).","journal-title":"Science"},{"key":"2505_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 349, 704\u2013706 (1991).","journal-title":"Nature"},{"key":"2505_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol. Sci. 12, 383\u2013388 (1991).","journal-title":"Trends Pharmacol. Sci."},{"key":"2505_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe, D. J. The molecular pathology of Alzheimer\u2019s disease. Neuron 6, 487\u2013498 (1991).","journal-title":"Neuron"},{"key":"2505_CR17","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"key":"2505_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","volume":"79","author":"C Strikwerda-Brown","year":"2022","unstructured":"Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 79, 975\u2013985 (2022).","journal-title":"JAMA Neurol."},{"key":"2505_CR19","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.neuron.2022.03.034","volume":"110","author":"WJ Lee","year":"2022","unstructured":"Lee, W. J. et al. Regional A\u03b2\u2013tau interactions promote onset and acceleration of Alzheimer\u2019s disease tau spreading. Neuron 110, 1932\u20131943 (2022).","journal-title":"Neuron"},{"key":"2505_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-05491-6","volume":"612","author":"P Yuan","year":"2022","unstructured":"Yuan, P. et al. PLD3 affects axonal spheroids and network defects in Alzheimer\u2019s disease. Nature 612, 328\u2013337 (2022).","journal-title":"Nature"},{"key":"2505_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nm.4443","volume":"24","author":"Z He","year":"2018","unstructured":"He, Z. et al. Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29\u201338 (2018).","journal-title":"Nat. Med."},{"key":"2505_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat. Neurosci. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci."},{"key":"2505_CR23","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.immuni.2022.10.016","volume":"55","author":"X Chen","year":"2022","unstructured":"Chen, X. & Holtzman, D. M. Emerging roles of innate and adaptive immunity in Alzheimer\u2019s disease. Immunity 55, 2236\u20132254 (2022).","journal-title":"Immunity"},{"key":"2505_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat. Genet. 54, 412\u2013436 (2022).","journal-title":"Nat. Genet."},{"key":"2505_CR25","doi-asserted-by":"publisher","unstructured":"Nutma, E. et al. Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Preprint at https:\/\/doi.org\/10.1101\/2022.05.11.491453 (2022).","DOI":"10.1101\/2022.05.11.491453"},{"key":"2505_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/cei.13649","volume":"206","author":"W Beaino","year":"2021","unstructured":"Beaino, W. et al. Towards PET imaging of the dynamic phenotypes of microglia. Clin. Exp. Immunol. 206, 282\u2013300 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"2505_CR27","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal, T. A. et al. Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 27, 1592\u20131599 (2021).","journal-title":"Nat. Med."},{"key":"2505_CR28","doi-asserted-by":"publisher","first-page":"eabe5640","DOI":"10.1126\/scitranslmed.abe5640","volume":"13","author":"X Xiang","year":"2021","unstructured":"Xiang, X. et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci. Transl. Med. 13, eabe5640 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2505_CR29","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686 (2022).","journal-title":"Alzheimers Dement."},{"key":"2505_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk, P. et al. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 55, 813\u2013822 (2017).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"2505_CR31","unstructured":"US Food and Drug Administration. FDA permits marketing for new test to improve diagnosis of Alzheimer\u2019s disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-new-test-improve-diagnosis-alzheimers-disease (2022)."},{"key":"2505_CR32","first-page":"e688","volume":"98","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology 98, e688\u2013e699 (2022).","journal-title":"Neurology"},{"key":"2505_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acn3.51670","volume":"9","author":"AJ Aschenbrenner","year":"2022","unstructured":"Aschenbrenner, A. J. et al. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann. Clin. Transl. Neurol. 9, 1739\u20131751 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2505_CR34","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell 183, 1699\u20131713 (2020).","journal-title":"Cell"},{"key":"2505_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"2505_CR36","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol. Med. 12, e12921 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2505_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19543-w","volume":"11","author":"JP Chhatwal","year":"2020","unstructured":"Chhatwal, J. P. et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat. Commun. 11, 6024 (2020).","journal-title":"Nat. Commun."},{"key":"2505_CR38","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298 (2018).","journal-title":"Neuron"},{"key":"2505_CR39","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","journal-title":"J. Exp. Med."},{"key":"2505_CR40","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2022).","journal-title":"Brain"},{"key":"2505_CR41","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1002\/alz.12906","volume":"19","author":"D Aguillon","year":"2022","unstructured":"Aguillon, D. et al. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer\u2019s disease. Alzheimers Dement. 19, 2585\u20132594 (2022).","journal-title":"Alzheimers Dement."},{"key":"2505_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie, K., Barth\u00e9lemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain 144, 515\u2013527 (2021).","journal-title":"Brain"},{"key":"2505_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awz346","volume":"143","author":"K Blennow","year":"2019","unstructured":"Blennow, K. et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain 143, 650\u2013660 (2019).","journal-title":"Brain"},{"key":"2505_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190 (2017).","journal-title":"Nature"},{"key":"2505_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13195-022-01142-0","volume":"14","author":"J Simr\u00e9n","year":"2022","unstructured":"Simr\u00e9n, J. et al. CSF tau368\/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. Alzheimer\u2019s Res. Ther. 14, 192 (2022).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"2505_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tins.2020.04.007","volume":"43","author":"I Fischer","year":"2020","unstructured":"Fischer, I. & Baas, P. W. Resurrecting the mysteries of big tau. Trends Neurosci. 43, 493\u2013504 (2020).","journal-title":"Trends Neurosci."},{"key":"2505_CR47","first-page":"1162","volume":"146","author":"F Gonzalez-Ortiz","year":"2022","unstructured":"Gonzalez-Ortiz, F. et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain 146, 1162\u20131165 (2022).","journal-title":"Brain"},{"key":"2505_CR48","doi-asserted-by":"publisher","unstructured":"Chatterjee, P. et al. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: associations with A\u03b2-PET, neurodegeneration, and cognition. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12879 (2022).","DOI":"10.1002\/alz.12879"},{"key":"2505_CR49","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira, J. B. et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144, 3505\u20133516 (2021).","journal-title":"Brain"},{"key":"2505_CR50","doi-asserted-by":"publisher","first-page":"e16987","DOI":"10.15252\/emmm.202216987","volume":"15","author":"D Biel","year":"2023","unstructured":"Biel, D. et al. sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer\u2019s disease. EMBO Mol. Med. 15, e16987 (2023).","journal-title":"EMBO Mol. Med."},{"key":"2505_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3233\/JAD-215635","volume":"87","author":"M Cao","year":"2022","unstructured":"Cao, M. et al. ABI3 is a novel early biomarker of Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 87, 335\u2013344 (2022).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"2505_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","volume":"577","author":"D Gate","year":"2020","unstructured":"Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease. Nature 577, 399\u2013404 (2020).","journal-title":"Nature"},{"key":"2505_CR53","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1016\/j.cell.2022.11.019","volume":"185","author":"N Piehl","year":"2022","unstructured":"Piehl, N. et al. Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment. Cell 185, 5028\u20135039 (2022).","journal-title":"Cell"},{"key":"2505_CR54","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/jnnp-2021-328646","volume":"93","author":"S Halbgebauer","year":"2022","unstructured":"Halbgebauer, S. et al. CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 93, 1059\u20131065 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2505_CR55","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","volume":"5","author":"D Galasko","year":"2019","unstructured":"Galasko, D. et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 5, 871\u2013882 (2019).","journal-title":"Alzheimer\u2019s Dement."},{"key":"2505_CR56","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.neuron.2016.07.007","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 494\u2013496 (2016).","journal-title":"Neuron"},{"key":"2505_CR57","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s43587-021-00028-4","volume":"1","author":"SA Kaeser","year":"2021","unstructured":"Kaeser, S. A. et al. A neuronal blood marker is associated with mortality in old age. Nat. Aging 1, 218\u2013225 (2021).","journal-title":"Nat. Aging"},{"key":"2505_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"2505_CR59","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/alz.12293","volume":"17","author":"KZ Gianattasio","year":"2021","unstructured":"Gianattasio, K. Z. et al. Generalizability of findings from a clinical sample to a community-based sample: a comparison of ADNI and ARIC. Alzheimers Dement. 17, 1265\u20131276 (2021).","journal-title":"Alzheimers Dement."},{"key":"2505_CR60","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"2505_CR61","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1093\/brain\/awac484","volume":"146","author":"JK Wisch","year":"2022","unstructured":"Wisch, J. K. et al. Proteomic clusters underlie heterogeneity in preclinical Alzheimer\u2019s disease progression. Brain 146, 2944\u20132956 (2022).","journal-title":"Brain"},{"key":"2505_CR62","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41593-021-00886-6","volume":"24","author":"C Yang","year":"2021","unstructured":"Yang, C. et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat. Neurosci. 24, 1302\u20131312 (2021).","journal-title":"Nat. Neurosci."},{"key":"2505_CR63","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"2505_CR64","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"2505_CR65","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 378, 1691\u20131703 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","volume":"6","author":"R Vassar","year":"2014","unstructured":"Vassar, R. BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 6, 89 (2014).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"2505_CR68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","volume":"54","author":"J-Y Hur","year":"2022","unstructured":"Hur, J.-Y. \u03b3-Secretase in Alzheimer\u2019s disease. Exp. Mol. Med 54, 433\u2013446 (2022).","journal-title":"Exp. Mol. Med"},{"key":"2505_CR69","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 311\u2013321 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR70","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki, S. et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 79, 1113\u20131121 (2022).","journal-title":"JAMA Neurol."},{"key":"2505_CR71","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish, N. J. et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N. Engl. J. Med. 388, 478\u2013479 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi, M. et al. Amyloid-related imaging abnormalities and \u03b2-amyloid\u2013targeting antibodies: a systematic review. JAMA Neurol. 79, 291\u2013304 (2022).","journal-title":"JAMA Neurol."},{"key":"2505_CR73","doi-asserted-by":"publisher","first-page":"e069402","DOI":"10.1002\/alz.069402","volume":"18","author":"L Reyderman","year":"2022","unstructured":"Reyderman, L. et al. Modeled impact of APOE4 genotype on ARIA-E incidence in patients treated with lecanemab. Alzheimer\u2019s Dement. 18, e069402 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"2505_CR74","doi-asserted-by":"publisher","first-page":"e1809","DOI":"10.1212\/WNL.0000000000012778","volume":"97","author":"L Antolini","year":"2021","unstructured":"Antolini, L. et al. Spontaneous ARIA-like events in cerebral amyloid angiopathy\u2013related Inflammation: a multicenter prospective longitudinal cohort study. Neurology 97, e1809\u2013e1822 (2021).","journal-title":"Neurology"},{"key":"2505_CR75","doi-asserted-by":"publisher","first-page":"eabd7522","DOI":"10.1126\/scitranslmed.abd7522","volume":"13","author":"M Xiong","year":"2021","unstructured":"Xiong, M. et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2505_CR76","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat. Med. 27, 1187\u20131196 (2021).","journal-title":"Nat. Med."},{"key":"2505_CR77","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"2505_CR78","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin, N. et al. Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann. Neurol. 92, 729\u2013744 (2022).","journal-title":"Ann. Neurol."},{"key":"2505_CR79","unstructured":"US Food and Drug Administration. FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval (2023)."},{"key":"2505_CR80","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","volume":"79","author":"MS Rafii","year":"2022","unstructured":"Rafii, M. S. et al. Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with Down syndrome: a phase 1b randomized clinical trial. JAMA Neurol. 79, 565\u2013574 (2022).","journal-title":"JAMA Neurol."},{"key":"2505_CR81","doi-asserted-by":"publisher","first-page":"e20202560","DOI":"10.1084\/jem.20202560","volume":"218","author":"KD Rynearson","year":"2021","unstructured":"Rynearson, K. D. et al. Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. J. Exp. Med. 218, e20202560 (2021).","journal-title":"J. Exp. Med."},{"key":"2505_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28941-1","volume":"13","author":"MT Duong","year":"2022","unstructured":"Duong, M. T. et al. Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer\u2019s disease. Nat. Commun. 13, 1495 (2022).","journal-title":"Nat. Commun."},{"key":"2505_CR83","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/alz.12453","volume":"18","author":"BP Imbimbo","year":"2022","unstructured":"Imbimbo, B. P., Ippati, S., Watling, M. & Balducci, C. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimer\u2019s Dement. 18, 1008\u20131037 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"2505_CR84","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng, E. et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 79, 758\u2013767 (2022).","journal-title":"JAMA Neurol."},{"key":"2505_CR85","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","volume":"146","author":"H Florian","year":"2023","unstructured":"Florian, H. et al. Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain 146, 2275\u20132284 (2023).","journal-title":"Brain"},{"key":"2505_CR86","doi-asserted-by":"publisher","first-page":"eabh1448","DOI":"10.1126\/sciadv.abh1448","volume":"7","author":"G Meisl","year":"2021","unstructured":"Meisl, G. et al. In vivo rate-determining steps of tau seed accumulation in Alzheimer\u2019s disease. Sci. Adv. 7, eabh1448 (2021).","journal-title":"Sci. Adv."},{"key":"2505_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimer\u2019s Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimer\u2019s Dement."},{"key":"2505_CR88","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, eaag0481 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2505_CR89","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437\u20131447 (2023).","journal-title":"Nat. Med."},{"key":"2505_CR90","unstructured":"Biogen. New data presented at AD\/PD 2023 show Biogen\u2019s BIIB080 (MAPT ASO) substantially reduced tau protein levels in patients with early-stage Alzheimer\u2019s disease. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-data-presented-adpdtm-2023-show-biogens-biib080-mapt-aso (2023)."},{"key":"2505_CR91","first-page":"e12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement. 8, e12295 (2022).","journal-title":"Alzheimers Dement."},{"key":"2505_CR92","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","volume":"26","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer\u2019s disease. Nat. Med. 26, 131\u2013142 (2020).","journal-title":"Nat. Med."},{"key":"2505_CR93","doi-asserted-by":"publisher","unstructured":"Zeng, H. et al. Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer\u2019s disease. Nat. Neurosci. https:\/\/doi.org\/10.1038\/s41593-022-01251-x (2023).","DOI":"10.1038\/s41593-022-01251-x"},{"key":"2505_CR94","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","volume":"182","author":"W-T Chen","year":"2020","unstructured":"Chen, W.-T. et al. Spatial transcriptomics and in situ sequencing to study Alzheimer\u2019s disease. Cell 182, 976\u2013991 (2020).","journal-title":"Cell"},{"key":"2505_CR95","doi-asserted-by":"publisher","first-page":"e20200785","DOI":"10.1084\/jem.20200785","volume":"217","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model. J. Exp. Med. 217, e20200785 (2020).","journal-title":"J. Exp. Med."},{"key":"2505_CR96","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","volume":"22","author":"CEG Leyns","year":"2019","unstructured":"Leyns, C. E. G. et al. TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22, 1217\u20131222 (2019).","journal-title":"Nat. Neurosci."},{"key":"2505_CR97","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1172\/JCI138179","volume":"130","author":"M Gratuze","year":"2020","unstructured":"Gratuze, M. et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest. 130, 4954\u20134968 (2020).","journal-title":"J. Clin. Invest."},{"key":"2505_CR98","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1073\/pnas.1710311114","volume":"114","author":"CEG Leyns","year":"2017","unstructured":"Leyns, C. E. G. et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl Acad. Sci. USA 114, 11524\u201311529 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2505_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00588-y","volume":"17","author":"J Hou","year":"2022","unstructured":"Hou, J., Chen, Y., Grajales-Reyes, G. & Colonna, M. TREM2 dependent and independent functions of microglia in Alzheimer\u2019s disease. Mol. Neurodegener. 17, 84 (2022).","journal-title":"Mol. Neurodegener."},{"key":"2505_CR100","doi-asserted-by":"publisher","first-page":"e20220654","DOI":"10.1084\/jem.20220654","volume":"220","author":"N Jain","year":"2022","unstructured":"Jain, N., Lewis, C. A., Ulrich, J. D. & Holtzman, D. M. Chronic TREM2 activation exacerbates A\u03b2-associated tau seeding and spreading. J. Exp. Med. 220, e20220654 (2022).","journal-title":"J. Exp. Med."},{"key":"2505_CR101","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1016\/j.neuron.2022.10.015","volume":"110","author":"C Romero-Molina","year":"2022","unstructured":"Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E. & Goate, A. M. Microglial efferocytosis: diving into the Alzheimer\u2019s disease gene pool. Neuron 110, 3513\u20133533 (2022).","journal-title":"Neuron"},{"key":"2505_CR102","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1016\/j.cell.2022.11.029","volume":"185","author":"S Morioka","year":"2022","unstructured":"Morioka, S. et al. Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation. Cell 185, 4887\u20134903 (2022).","journal-title":"Cell"},{"key":"2505_CR103","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neuron.2022.10.022","volume":"111","author":"M Gratuze","year":"2023","unstructured":"Gratuze, M. et al. TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. Neuron 111, 202\u2013219 (2023).","journal-title":"Neuron"},{"key":"2505_CR104","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-021-03734-6","volume":"595","author":"CS McAlpine","year":"2021","unstructured":"McAlpine, C. S. et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer\u2019s disease. Nature 595, 701\u2013706 (2021).","journal-title":"Nature"},{"key":"2505_CR105","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.neuron.2021.03.024","volume":"109","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron 109, 1657\u20131674 (2021).","journal-title":"Neuron"},{"key":"2505_CR106","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s43587-023-00368-3","volume":"3","author":"N Koutsodendris","year":"2023","unstructured":"Koutsodendris, N. et al. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nat. Aging 3, 275\u2013296 (2023).","journal-title":"Nat. Aging"},{"key":"2505_CR107","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/ana.26043","volume":"89","author":"A Litvinchuk","year":"2021","unstructured":"Litvinchuk, A. et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model. Ann. Neurol. 89, 952\u2013966 (2021).","journal-title":"Ann. Neurol."},{"key":"2505_CR108","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"T-PV Huynh","year":"2017","unstructured":"Huynh, T. -P. V. et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron 96, 1013\u20131023 (2017).","journal-title":"Neuron"},{"key":"2505_CR109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41586-021-03489-0","volume":"593","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita, S. et al. Meningeal lymphatics affect microglia responses and anti-A\u03b2 immunotherapy. Nature 593, 255\u2013260 (2021).","journal-title":"Nature"},{"key":"2505_CR110","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41593-023-01257-z","volume":"26","author":"S De Schepper","year":"2023","unstructured":"De Schepper, S. et al. Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 26, 406\u2013415 (2023).","journal-title":"Nat. Neurosci."},{"key":"2505_CR111","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-022-05397-3","volume":"611","author":"A Drieu","year":"2022","unstructured":"Drieu, A. et al. Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid. Nature 611, 585\u2013593 (2022).","journal-title":"Nature"},{"key":"2505_CR112","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41586-023-05788-0","volume":"615","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature 615, 668\u2013677 (2023).","journal-title":"Nature"},{"key":"2505_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00595-7","volume":"18","author":"S Chandra","year":"2023","unstructured":"Chandra, S., Sisodia, S. S. & Vassar, R. J. The gut microbiome in Alzheimer\u2019s disease: what we know and what remains to be explored. Mol. Neurodegener. 18, 9 (2023).","journal-title":"Mol. Neurodegener."},{"key":"2505_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11047-w","volume":"7","author":"MR Minter","year":"2017","unstructured":"Minter, M. R. et al. Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE\/PS1\u0394E9 murine model of Alzheimer\u2019s disease. Sci. Rep. 7, 10411 (2017).","journal-title":"Sci. Rep."},{"key":"2505_CR115","doi-asserted-by":"publisher","first-page":"41802","DOI":"10.1038\/srep41802","volume":"7","author":"T Harach","year":"2017","unstructured":"Harach, T. et al. Reduction of A\u03b2 amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep. 7, 41802 (2017).","journal-title":"Sci. Rep."},{"key":"2505_CR116","doi-asserted-by":"publisher","first-page":"eadd1236","DOI":"10.1126\/science.add1236","volume":"379","author":"D Seo","year":"2023","unstructured":"Seo, D. et al. ApoE isoform\u2013 and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science 379, eadd1236 (2023).","journal-title":"Science"},{"key":"2505_CR117","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1212\/WNL.0000000000007654","volume":"92","author":"RJ Cannistraro","year":"2019","unstructured":"Cannistraro, R. J. et al. CNS small vessel disease: a clinical review. Neurology 92, 1146\u20131156 (2019).","journal-title":"Neurology"},{"key":"2505_CR118","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-022-05440-3","volume":"612","author":"J Wagner","year":"2022","unstructured":"Wagner, J. et al. Medin co-aggregates with vascular amyloid-\u03b2 in Alzheimer\u2019s disease. Nature 612, 123\u2013131 (2022).","journal-title":"Nature"},{"key":"2505_CR119","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41590-018-0232-x","volume":"19","author":"JK Ryu","year":"2018","unstructured":"Ryu, J. K. et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat. Immunol. 19, 1212\u20131223 (2018).","journal-title":"Nat. Immunol."},{"key":"2505_CR120","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s42003-022-04398-2","volume":"6","author":"N Verma","year":"2023","unstructured":"Verma, N. et al. A\u03b2 efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas. Commun. Biol. 6, 2 (2023).","journal-title":"Commun. Biol."},{"key":"2505_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00503-x","volume":"16","author":"A Meneses","year":"2021","unstructured":"Meneses, A. et al. TDP-43 pathology in Alzheimer\u2019s disease. Mol. Neurodegener. 16, 84 (2021).","journal-title":"Mol. Neurodegener."},{"key":"2505_CR122","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41586-022-04650-z","volume":"605","author":"M Schweighauser","year":"2022","unstructured":"Schweighauser, M. et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature 605, 310\u2013314 (2022).","journal-title":"Nature"},{"key":"2505_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar, C. et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 62 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"2505_CR124","doi-asserted-by":"publisher","unstructured":"Irwin, K. E. et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. Preprint at https:\/\/doi.org\/10.1101\/2023.01.23.525202 (2023).","DOI":"10.1101\/2023.01.23.525202"},{"key":"2505_CR125","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41593-022-01222-2","volume":"26","author":"MH Murdock","year":"2023","unstructured":"Murdock, M. H. & Tsai, L.-H. Insights into Alzheimer\u2019s disease from single-cell genomic approaches. Nat. Neurosci. 26, 181\u2013195 (2023).","journal-title":"Nat. Neurosci."},{"key":"2505_CR126","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nrn3896","volume":"16","author":"SA Small","year":"2015","unstructured":"Small, S. A. & Petsko, G. A. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 16, 126\u2013132 (2015).","journal-title":"Nat. Rev. Neurosci."},{"key":"2505_CR127","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41588-021-00894-z","volume":"53","author":"S Morabito","year":"2021","unstructured":"Morabito, S. et al. Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer\u2019s disease. Nat. Genet. 53, 1143\u20131155 (2021).","journal-title":"Nat. Genet."},{"key":"2505_CR128","doi-asserted-by":"publisher","first-page":"100263","DOI":"10.1016\/j.xgen.2023.100263","volume":"3","author":"AG Anderson","year":"2023","unstructured":"Anderson, A. G. et al. Single nucleus multiomics identifies ZEB1 and MAFB as candidate regulators of Alzheimer\u2019s disease-specific cis-regulatory elements. Cell Genom. 3, 100263 (2023).","journal-title":"Cell Genom."},{"key":"2505_CR129","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-022-05439-w","volume":"611","author":"JW Blanchard","year":"2022","unstructured":"Blanchard, J. W. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature 611, 769\u2013779 (2022).","journal-title":"Nature"},{"key":"2505_CR130","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/brain\/awac354","volume":"146","author":"J van Arendonk","year":"2023","unstructured":"van Arendonk, J. et al. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study. Brain 146, 337\u2013348 (2023).","journal-title":"Brain"},{"key":"2505_CR131","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-021-04183-x","volume":"600","author":"Z De Miguel","year":"2021","unstructured":"De Miguel, Z. et al. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature 600, 494\u2013499 (2021).","journal-title":"Nature"},{"key":"2505_CR132","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413\u2013446 (2020).","journal-title":"Lancet"},{"key":"2505_CR133","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-019-0478-5","volume":"45","author":"C Wang","year":"2020","unstructured":"Wang, C. & Holtzman, D. M. Bidirectional relationship between sleep and Alzheimer\u2019s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology 45, 104\u2013120 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"2505_CR134","unstructured":"ALZFORUM. Gantenerumab mystery: how did it lose potency in phase 3? https:\/\/www.alzforum.org\/news\/conference-coverage\/gantenerumab-mystery-how-did-it-lose-potency-phase-3"},{"key":"2505_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11674-z","volume":"10","author":"E Spangenberg","year":"2019","unstructured":"Spangenberg, E. et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer\u2019s disease model. Nat. Commun. 10, 3758 (2019).","journal-title":"Nat. Commun."},{"key":"2505_CR136","doi-asserted-by":"publisher","first-page":"110961","DOI":"10.1016\/j.celrep.2022.110961","volume":"39","author":"S Kiani Shabestari","year":"2022","unstructured":"Kiani Shabestari, S. et al. Absence of microglia promotes diverse pathologies and early lethality in Alzheimer\u2019s disease mice. Cell Rep. 39, 110961 (2022).","journal-title":"Cell Rep."},{"key":"2505_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0244-x","volume":"13","author":"J Sosna","year":"2018","unstructured":"Sosna, J. et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 13, 11 (2018).","journal-title":"Mol. Neurodegener."},{"key":"2505_CR138","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.neuron.2016.05.003","volume":"90","author":"P Yuan","year":"2016","unstructured":"Yuan, P. et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90, 724\u2013739 (2016).","journal-title":"Neuron"},{"key":"2505_CR139","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. TREM2 lipid sensing sustains microglia response in an Alzheimer\u2019s disease model. Cell 160, 1061\u20131071 (2015).","journal-title":"Cell"},{"key":"2505_CR140","doi-asserted-by":"publisher","first-page":"e20210542","DOI":"10.1084\/jem.20210542","volume":"218","author":"M Gratuze","year":"2021","unstructured":"Gratuze, M. et al. Activated microglia mitigate A\u03b2-associated tau seeding and spreading. J. Exp. Med. 218, e20210542 (2021).","journal-title":"J. Exp. Med."},{"key":"2505_CR141","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1084\/jem.20190980","volume":"216","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 216, 2546\u20132561 (2019).","journal-title":"J. Exp. Med."},{"key":"2505_CR142","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1093\/brain\/awz241","volume":"142","author":"R Mancuso","year":"2019","unstructured":"Mancuso, R. et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142, 3243\u20133264 (2019).","journal-title":"Brain"},{"key":"2505_CR143","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0197-4580(88)80079-4","volume":"9","author":"J Rogers","year":"1988","unstructured":"Rogers, J., Luber-Narod, J., Styren, S. D. & Civin, W. H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer\u2019s disease. Neurobiol. Aging 9, 339\u2013349 (1988).","journal-title":"Neurobiol. Aging"},{"key":"2505_CR144","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000486200","volume":"18","author":"M Merlini","year":"2018","unstructured":"Merlini, M. et al. Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study. Neurodegener. Dis. 18, 49\u201356 (2018).","journal-title":"Neurodegener. Dis."},{"key":"2505_CR145","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/359322a0","volume":"359","author":"C Haass","year":"1992","unstructured":"Haass, C. et al. Amyloid \u03b2-peptide is produced by cultured cells during normal metabolism. Nature 359, 322\u2013325 (1992).","journal-title":"Nature"},{"key":"2505_CR146","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"EI Rogaev","year":"1995","unstructured":"Rogaev, E. I. et al. Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature 376, 775\u2013778 (1995).","journal-title":"Nature"},{"key":"2505_CR147","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science 269, 973\u2013977 (1995).","journal-title":"Science"},{"key":"2505_CR148","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 375, 754\u2013760 (1995).","journal-title":"Nature"},{"key":"2505_CR149","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner, D. et al. Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat. Med. 2, 864\u2013870 (1996).","journal-title":"Nat. Med."},{"key":"2505_CR150","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nn0901-887","volume":"4","author":"C Nilsberth","year":"2001","unstructured":"Nilsberth, C. et al. The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced A\u03b2 protofibril formation. Nat. Neurosci. 4, 887\u2013893 (2001).","journal-title":"Nat. Neurosci."},{"key":"2505_CR151","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(22)00408-2","volume":"22","author":"AH Boerwinkle","year":"2023","unstructured":"Boerwinkle, A. H. et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer\u2019s disease: a cross-sectional study. Lancet Neurol. 22, 55\u201365 (2023).","journal-title":"Lancet Neurol."},{"key":"2505_CR152","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson, T. et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature 488, 96\u201399 (2012).","journal-title":"Nature"},{"key":"2505_CR153","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega, K. G. et al. Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease. Science 330, 1774\u20131774 (2010).","journal-title":"Science"},{"key":"2505_CR154","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano, J. M. et al. Human apoE Isoforms differentially regulate brain Amyloid-\u03b2 peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2505_CR155","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. J. Am. Med. Assoc. 313, 1924\u20131938 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"2505_CR156","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde, R. et al. A\u03b242-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940\u2013946 (2006).","journal-title":"EMBO Rep."},{"key":"2505_CR157","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito, T. et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 17, 661\u2013663 (2014).","journal-title":"Nat. Neurosci."},{"key":"2505_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00547-7","volume":"17","author":"D Xia","year":"2022","unstructured":"Xia, D. et al. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol. Neurodegener. 17, 41 (2022).","journal-title":"Mol. Neurodegener."},{"key":"2505_CR159","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ana.26643","volume":"93","author":"ES Musiek","year":"2023","unstructured":"Musiek, E. S., McDade, E. & Holtzman, D. M. Lecanamab ushers in a new era of anti-amyloid therapy for Alzheimer\u2019s disease. Ann. Neurol. 93, 877\u2013880 (2023).","journal-title":"Ann. Neurol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02505-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02505-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02505-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:01:40Z","timestamp":1783670500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02505-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":159,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02505-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.K.S. declares no competing interests. D.M.H. cofounded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Cajal Neuroscience and Genentech and consults for Asteroid Therapeutics. D.M.H. is an inventor on a patent on APOE antibodies that was licensed by Washington University to NextCure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}